Hydration Pharmaceuticals Full Year 2024 Earnings: US$0.02 loss per share (vs US$0.037 loss in FY 2023)

Hydration Pharmaceuticals (ASX:HPC) Full Year 2024 Results

Key Financial Results

• Revenue: US$3.20m (down 26% from FY 2023).
• Net loss: US$5.67m (loss narrowed by 22% from FY 2023).
• US$0.02 loss per share (improved from US$0.037 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Hydralyte Group contributing US$3.20m. The largest operating expense was General & Administrative costs, amounting to US$3.05m (42% of total expenses). Explore how HPC's revenue and expenses shape its earnings.

Hydration Pharmaceuticals' share price is broadly unchanged from a week ago.

Risk Analysis

Before you take the next step you should know about the 5 warning signs for Hydration Pharmaceuticals (4 are a bit unpleasant!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.